Rapalogix Health develops a TORC1-targeting platform aimed at restoring youthful cellular function in skin and is building both a prescription therapeutics pipeline and professional skincare products. Its lead molecule, RLX-201, is a patented pro-longevity compound and powers the Re-Q Pro-Longevity Face Serum, which launched nationally on May 14, 2026 and is available at dermatology and aesthetic practices across the United States. The company is advancing RLX-202 as its next prescription therapeutic and is using Series A proceeds to fund IND-enabling studies for that candidate. Rapalogix plans to use capital from the financing to expand Re-Q Health nationally. The company has received multiple industry recognitions in 2026, including awards at IMCAS, Octane’s Aesthetics Tech Forum, INNOCOS, and AMWC. The business is led by Co-Founder and CEO Rahul Mehta, PhD.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2026